Ann: Update on First In Human DurAVR THV Study, page-9

Incredible.

Every month, every week, this company is exponentially increasing the value of its IP.

“The data so far is extremely encouraging and fulfilling the hypothesis that DurAVR™ works better and lasts longer. As we move into the second half, we will continue enrolling patients into our studies (Europe and FDA EFS) and gathering data for presentation at the major conferences as well as regulatory filings throughout the rest of the year. We will continue generating non-patient data as well with leading research institutions that demonstrate DurAVR’s™ superior flow characteristics compared with competitor valves as well as other relevant data,” Anteris CEO, Wayne Paterson, added.

Soon, it will be indisputable, that the DurAVR and ADAPT technologies are the best out there, the best technologies available. And we will have the best doctors (from our advisory board) promoting these claims and these results and these studies at the world's best conferences.

It's all working towards a perfect storm. A perfect storm where the DurAVR could (and this is still awhile off) could end up taking very close to 100% market share in a field estimated to be worth US$12 Billion in 2025 and US$14 Billion in 2028.

A potentially massive prize for either Anteris or anyone who buys us out.